P
PLIANT THERAPEUTICS INC
NASDAQ: PLRX (Pliant Therapeutics, Inc.)
最近更新时间: 22小时之前1.64
0.02 (1.23%)
| 前收盘价格 | 1.62 |
| 收盘价格 | 1.62 |
| 成交量 | 514,511 |
| 平均成交量 (3个月) | 1,224,896 |
| 市值 | 100,676,648 |
| 价格/销量 (P/S) | 3.07 |
| 股市价格/股市净资产 (P/B) | 0.460 |
| 52周波幅 | |
| 利润日期 | 6 Nov 2025 |
| 稀释每股收益 (EPS TTM) | -3.61 |
| 总债务/股东权益 (D/E MRQ) | 23.40% |
| 流动比率 (MRQ) | 11.03 |
| 营业现金流 (OCF TTM) | -174.10 M |
| 杠杆自由现金流 (LFCF TTM) | -112.84 M |
| 资产报酬率 (ROA TTM) | -33.89% |
| 股东权益报酬率 (ROE TTM) | -63.22% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看跌 |
| Biotechnology (全球的) | 混合的 | 看跌 | |
| 股票 | Pliant Therapeutics, Inc. | 看涨 | 看跌 |
AIStockmoo 评分
0.4
| 分析师共识 | 1.5 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 1.5 |
| 技术振荡指标 | 0.5 |
| 平均 | 0.38 |
|
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 3.04% |
| 机构持股比例 | 95.97% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Tang Capital Management Llc | 30 Jun 2025 | 6,000,000 |
| Deep Track Capital, Lp | 30 Jun 2025 | 3,947,807 |
| Blue Owl Capital Holdings Lp | 30 Jun 2025 | 2,969,199 |
| Woodline Partners Lp | 30 Jun 2025 | 2,348,526 |
| Madison Avenue Partners, Lp | 30 Jun 2025 | 2,230,012 |
| Trv Gp Iv, Llc | 30 Jun 2025 | 2,132,867 |
| Redmile Group, Llc | 30 Jun 2025 | 1,632,577 |
| Acadian Asset Management Llc | 30 Jun 2025 | 1,630,413 |
| Peapod Lane Capital Llc | 30 Jun 2025 | 893,730 |
| 52周波幅 | ||
| 中 | 4.00 (143.90%) | |
| 总计 | 1 购买 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Piper Sandler | 08 Aug 2025 | 4.00 (143.90%) | 购买 | 1.66 |
| 日期 | 类型 | 细节 |
|---|---|---|
| 07 Aug 2025 | 公告 | Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results |
| 27 Jun 2025 | 公告 | Pliant Therapeutics Provides Update on BEACON-IPF |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合